Acromegaly: Beyond surgery
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels. Significant progress has been made in the development of medical therapies to achieve biochemical and symptomatic control in acr...
Main Authors: | Gaya Thanabalasingham, Ashley B Grossman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=4;spage=563;epage=567;aulast=Thanabalasingham |
Similar Items
-
New opportunities for secondary drug therapy of acromegaly
by: V. S. Pronin, et al.
Published: (2020-05-01) -
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
by: Hélène Lasolle, et al.
Published: (2019-10-01) -
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
by: Sang Ouk Chin, et al.
Published: (2019-03-01) -
Novel Somatostatin Receptor Ligands Therapies for Acromegaly
by: Rosa Maria Paragliola, et al.
Published: (2018-03-01) -
Long-term Primary Medical Therapy with Somatostatin Analogs in Acromegaly
by: Deng-Huang Su
Published: (2006-01-01)